BOULDER, Colo., April 25 /PRNewswire/ -- Source MDx announced today that Karl Wassmann, President and CEO, is scheduled to chair a session at Cambridge Healthtech Institute's Inaugural Targeting Cancer Diagnostics Conference. The conference is part of The G.O.T. Summit, and is taking place at the World Trade Center in Boston, Massachusetts from April 26 to 27.
On April 26 at 2:00 Mr. Wassmann will chair a session titled "Biomarker Development -- Gene Expression for Cancer Diagnostics." The session will take place in the Cityview 1 room. Mr. Wassmann will provide opening remarks for the Cancer Biomarker Development session, which will include speakers from Lilly Research Laboratories, University of California - Irvine and Iconix Pharmaceuticals. The session will provide information about new approaches and technologies for cancer biomarker development from blood samples including Promoter Arrays, Chemogenomics, micro RNA and Immunomagnetic Circulating Tumor Cells ("CTC") Selection and QPCR. Source MDx is also exhibiting at the conference at booth #17.
About Source MDx
Source MDx is focused on the development of RNA-based biomarkers and companion diagnostics in inflammation related therapeutic areas including oncology, cardiovascular, autoimmune and infectious diseases for pharmaceutical and biotech companies. Founded in 1998, Source MDx has pioneered the precision measurement and clinical utility of RNA-based biomarkers in the characterization of inflammation and immune response. Source MDx is an industry leader in demonstrating the ability to monitor an individual's health, disease status and response to therapy at the molecular level based on RNA from whole blood, tissue and biofluid samples.
Source MDxCONTACT: Michelle Linn for Source MDx, +1-508-419-1555,linnmich@sourcemdx.com.
Web site: http://www.sourcemdx.com/
